Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007398
Filing Date
2025-05-12
Accepted
2025-05-12 16:29:21
Documents
58
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20250331x10q.htm   iXBRL 10-Q 1514870
2 EX-31.1 tbph-20250331xex31d1.htm EX-31.1 13337
3 EX-31.2 tbph-20250331xex31d2.htm EX-31.2 14140
4 EX-32 tbph-20250331xex32.htm EX-32 16103
  Complete submission text file 0001558370-25-007398.txt   5783765

Data Files

Seq Description Document Type Size
5 EX-101.SCH tbph-20250331.xsd EX-101.SCH 39792
6 EX-101.CAL tbph-20250331_cal.xml EX-101.CAL 41439
7 EX-101.DEF tbph-20250331_def.xml EX-101.DEF 143440
8 EX-101.LAB tbph-20250331_lab.xml EX-101.LAB 338189
9 EX-101.PRE tbph-20250331_pre.xml EX-101.PRE 237613
61 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20250331x10q_htm.xml XML 916395
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 25935297
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)